WZWentao Zhong

Wentao Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wentao Zhong has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Huiyun Cai

    Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China

    4 shared publications
  • Junfeng Du

    The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China

    4 shared publications
  • Gang Chen

    Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China

    3 shared publications
  • Hongyan Zhu

    Department of Pathology, the 7th Medical Center, Chinese PLA General Hospital, Beijing, 100700, People’s Republic of China

    3 shared publications
  • Aijun Liu

    Department of Pathology, the 7th Medical Center, Chinese PLA General Hospital, Beijing, 100700, People’s Republic of China

    2 shared publications
  • Liang Sun

    Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Neutrophil Extracellular Traps Predict Prognosis and Neoadjuvant Immunotherapy Response in Gastric Cancer

    by Wentao Zhong, Qianyu Wang, Liang Sun, Hongyan Zhu, Huiyun Cai, Junhua Dong, Gang Chen, Aijun Liu, Junfeng Du

    Purpose: To determine whether neutrophil extracellular trap (NET) predicts prognosis and response to neoadjuvant immunotherapy in gastric cancer (GC) and explore the associated mechanisms. Patients and Methods: Transcriptomic data from a GEO dataset (GSE62254) comprising 300 GC patients were analyzed. Patients were clustered based on 69 predefined NET-related genes (NRGs) summarized in previous studies, and clinical characteristics and immune cell infiltration between clusters were compared. An NRG signature was constructed. Retrospective clinical data and tissue samples from 243 surgically resected GC patients without neoadjuvant therapy and 49 patients receiving neoadjuvant chemotherapy combined with immunotherapy were collected. RNA sequencing, immunohistochemistry, and immunofluorescence were performed to assess NET density and its clinical relevance. Results: Two NET-related subtypes in GC (NT1 and NT2) with distinct clinical features and survival time were identified. A risk model based on five NRGs demonstrated that NT2 had lower risk scores, correlating with favorable outcomes. High NET density was associated with advanced TNM stage and short recurrence-free survival time in the surgery cohort. In the immunotherapy cohort, low pre-treatment NET density correlated with more T cells predicted superior response rates (45.8% vs. 16.0%, P = 0.032) and pathological complete response (29.2% vs. 4.0%, P = 0.023). Conclusion: Low NET density is linked to better prognosis and may identify patients with GC who could benefit from immunotherapy. These findings highlight the important role of NET in GC.


  • Open Access

    Harnessing dental stem cell-derived synovial cells for IBD therapy: dual modulation of gut immunity and crypt repair

    by Haiyang Liu, Jiayu Zhang, Wentao Zhong, Sen Li, Lin Jing, Xiaohui Cui, Huiyun Cai, Shijie Yang, Fangming Kan, Sheng Yu, et al.


  • Open Access

    Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer

    by Qianyu Wang, Wentao Zhong, Xiaofei Shen, Zechen Hao, Meng Wan, Xiaopeng Yang, Ran An, Hongyan Zhu, Huiyun Cai, Tao Li, et al.

    Tertiary lymphoid structure (TLS) contributes to the anti-tumor immune response, and predicts the prognosis of colorectal cancer patients. However, the potential impact of TLS in shaping the immune status of rectal adenocarcinoma, and the intrinsic relationship between TLS and neoadjuvant therapies (neoTx) remain unclear. We performed hematoxylin-eosin staining, immunohistochemical and biomolecular analyses to investigate TLS and tumor-infiltrating lymphocytes (TILs) in 221 neoTx-treated and 242 treatment-naïve locally advanced rectal cancer (LARC) patients. High TLS density was significantly associated with the absence of vascular invasion, a lower neutrophil-to-lymphocyte ratio, increased TLS maturity, a longer recurrence-free survival (RFS) (hazard ratio [HR] 0.2985 95% confidence interval [CI] 0.1894–0.4706, p < 0.0001) and enhanced infiltration of adaptive immune cells. Biomolecular analysis showed that high TLS-score was strongly associated with more infiltration of immune cells and increased activation of immune-related pathways. TLS+ tumors in pre-treatment specimens were associated with a higher proportion of good respond (62.5% vs. 29.8%, p < 0.0002) and pathological complete remission (pCR) (40.0% vs. 11.1%, p < 0.0001), and significantly increased RFS (HR 0.3574 95%CI 0.1489–0.8578 p = 0.0213) compared with TLS- tumors in the neoTx cohort, which was confirmed in GSE119409 and GSE150082. Further studies showed that neoTx significantly reduced TLS density and maturity, and abolished the prognostic value of TLS. Our study illustrates that TLS may have a key role in mediating the T-cell-inflamed tumor microenvironment, which also provides a new direction for neoTx, especially neoadjuvant immunotherapy, in LRAC patients.


  • Open Access

    Neutrophil Extracellular Trap is Surrogate Biomarker for Prognosis and Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer

    by Wentao Zhong, Qianyu Wang, Xiaofei Shen, Yuan Lv, Liang Sun, Ran An, Hongyan Zhu, Huiyun Cai, Gang Chen, Aijun Liu, et al.

    Purpose: To demonstrate the intrinsic association of Neutrophil extracellular traps (NETs) with outcome and neoadjuvant therapy response of locally advanced rectal cancer (LARC), and the mechanisms. Patients and Methods: We enrolled 240 patients with LARC who underwent surgery without neoadjuvant therapy in two independent sets (training and validation), and 153 patients who received neoadjuvant therapy with biopsy followed by surgery. Immunohistochemistry, immunofluorescence staining and bioinformatics analysis were performed in formalin-fixed paraffin-embedded sections. NETs were identified by costaining for myeloperoxidase and citrullinated histone H3. Results: NETs were associated with recurrence-free survival in the surgical training and validation sets. High-NET density predicted poor postoperative survival of patients with LARC. Multivariate analysis identified NETs, TNM stage, and neutrophil-to-lymphocyte ratio as independent prognostic factors for recurrence-free survival. Low-NETs LARC demonstrated increased CD8+ T cell and lower T regulatory cell infiltration, which indicated a tumor immune microenvironment with strong antitumor capacity. High-NET density was associated with epithelial–mesenchymal transition, which is considered to contribute to tumor progression. In the neoadjuvant therapy cohort, high-NET density on biopsy was significantly associated with reduced likelihood of complete/near complete response. Conclusion: NET was an independent prognostic factor in LARC that were associated with patients’ survival, and NET density in pretreatment biopsies was an independent predictive biomarker of response to neoadjuvant therapy. This biomarker may be helpful in predicting survival in LARC with improved accuracy and selecting patients who will respond to neoadjuvant therapy.